[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369677-105":59,"doc-detail-369677-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-and-clinical-applications-of-liquid-biopsy-assays-in-cancer-screening","Development and clinical applications of liquid biopsy assays in cancer screening","","Liquid biopsy has become a research focus and a product-development hotspot in cancer screening. Advances in molecular biology have enabled multiple marker classes—including methylation, hydroxymethylation, mutations, copy number variation, and microRNA—to enter screening tests. This review summarizes clinical trials and studies of approved assays or tests under development in China across lung, HCC, colorectal, gastric, esophageal, and pan-cancer screening. It highlights promise for early detection while addressing challenges in sensitivity, specificity, standardization, cost-effectiveness, and future directions such as pan-cancer optimization, multi-omics integration, AI-assisted diagnosis, and large prospective trials.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-and-clinical-applications-of-liquid-biopsy-assays-in-cancer-screening/369677/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-and-clinical-applications-of-liquid-biopsy-assays-in-cancer-screening/369677.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-21","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What markers does the review cover in liquid biopsy for cancer screening?","Question",{"text":112,"@type":113},"The review covers methylation and hydroxymethylation, mutations, copy number variation, and microRNA (miRNA). It focuses on markers reported in screening assays and tests approved or under development in China.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which cancer screening applications are summarized?",{"text":117,"@type":113},"It reviews screening studies for lung cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, esophageal cancer, and multiple-cancer (pan-cancer) screening.",{"name":119,"@type":110,"acceptedAnswer":120},"What challenges limit liquid biopsy assays despite their potential?",{"text":121,"@type":113},"Key challenges include sensitivity and specificity, productization, standardization, and cost-effectiveness. Pan-cancer screening also needs optimization for detection performance and organ-specific recognition.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369677,1791030945,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Development and clinical applications of liquid biopsy assays in cancer screening  \nYing Han1\\#, Peiying Zhang2\\#, Yuan Gong3, Lele Song2,4  \n1Department of Hepatology and Gastroenterology, Beijing Youan Hospital, Capital Medical University, Beijing, China; 2Division of Cancer Early Screening, Genetron Health (Beijing) Co., Ltd., Beijing, China; 3Department of Gastroenterology, The Second Medical Center of the Chinese PLA General Hospital, Beijing, China; 4Department of Radiotherapy, The Eighth Medical Center of the Chinese PLA General Hospital, Beijing, China Contributions: (I) Conception and design: All authors; (II) Administrative support: Y Han, Y Gong, L Song; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: Y Han, P Zhang, L Song; (VI)  \nManuscript writing: All authors; (VII) Final approval of manuscript: All authors.  \n\\#These authors contributed equally to this work.  \nCorrespondence to: Dr. Lele Song, MD, PhD. Division of Cancer Early Screening, Genetron Health (Beijing) Co., Ltd., Beijing, China; Department of Radiotherapy, The Eighth Medical Center of the Chinese PLA General Hospital, No. 17 Heishanhu Road, Haidian District, Beijing 100091, China. Email: [songlele@sina.com](songlele@sina.com); Dr. Yuan Gong, MD. Department of Gastroenterology, The Second Medical Center of the Chinese PLA General  \nHospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. Email: [gongquanquan79@163.com](gongquanquan79@163.com).  \nAbstract: Liquid biopsy has become a research focus and a hotspot of product development in cancer screening. With the rapid development of molecular biology technology, many new markers have been identified and developed in cancer screening tests in recent years. This article reviews the development of novel liquid biopsy-based markers in cancer screening, including methylation, hydroxymethylation, mutation, copy number variation, and microRNA (miRNA), with specific focuses on clinical trials and studies from approved cancer screening assays or tests under development in China. Studies on screening of lung cancer, hepatocellular carcinoma (HCC), colorectal cancer, gastric cancer, esophageal cancer, and multiple cancers (pan-cancer screening) are reviewed and summarized. Liquid biopsy techniques detecting novel markers show great potential in the early screening of cancers, but still face challenges in sensitivity, specificity, productization, standardization, and cost-effectiveness. The emerging pan-cancer screening represents a direction of high-throughput and multiple cancer simultaneous screening, while it still needs optimization in detection performance and organ-specific recognition. Multi-omics integration analysis, artificial intelligence (AI)-assisted diagnosis, and large-scale prospective clinical studies will become important development steps in this field. Through a systematic review of the relevant literature, this paper describes in detail the development of new liquid biopsy technology, new progress in the field of cancer early screening, clinical application status, and future research direction. The review provides some useful insights into the future selection of early screening technology, the formulation of clinical research or trial protocols,  \nand the balance between performance and cost.  \nKeywords: Cancer; screening; liquid biopsy; methylation; mutation  \nSubmitted Feb 04, 2025. Accepted for publication Apr 17, 2025. Published online Jun 13, 2025.  \ndoi: 10.21037/tcr-2025-272  \nView this article at: [https://dx.doi.org/10.21037/tcr-2025-272](https://dx.doi.org/10.21037/tcr-2025-272)  \nIntroduction  \nThe early screening and diagnosis of cancer is very important to improve the survival rate and prognosis  \nof patients. Traditional serological protein markers have some limitations in tumor screening, such as low sensitivity and poor specificity. In recent years, with the r","cbCaibflvwu6wtP7","https://ap.wps.com/l/cbCaibflvwu6wtP7","pdf",335481,14,"English","# Introduction\n## Purpose and scope of the review\n## Background: limits of traditional protein markers\n## Liquid biopsy as a non-invasive approach\n# Clinical development and marker types\n## Methylation and hydroxymethylation\n## Mutation and copy number variation\n## microRNA (miRNA)\n# Cancer types covered\n## Lung cancer\n## Hepatocellular carcinoma\n## Colorectal and gastric cancer\n## Esophageal cancer and pan-cancer screening\n# Challenges and future directions","[{\"question\":\"What markers does the review cover in liquid biopsy for cancer screening?\",\"answer\":\"The review covers methylation and hydroxymethylation, mutations, copy number variation, and microRNA (miRNA). It focuses on markers reported in screening assays and tests approved or under development in China.\"},{\"question\":\"Which cancer screening applications are summarized?\",\"answer\":\"It reviews screening studies for lung cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, esophageal cancer, and multiple-cancer (pan-cancer) screening.\"},{\"question\":\"What challenges limit liquid biopsy assays despite their potential?\",\"answer\":\"Key challenges include sensitivity and specificity, productization, standardization, and cost-effectiveness. Pan-cancer screening also needs optimization for detection performance and organ-specific recognition.\"}]","Development and clinical applications of liquid biopsy assays in cancer screening | PDF",1790184069,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/400bd4e3cb028f3e3cfec4a2daaaf8c4.webp",983,1287,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9beb56dce5c86ba57b53049b78df9a7.webp",982,1286,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a51d0d16ad5e19421b2b66261dad4990.webp",981,642,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b99fef274ba5321596172554cec1606.webp",980,641]